Ann: Change of Director's Interest Notice - Grant Chamberlain, page-3

Howdy claude, immutep's tacti-002 and aipac trials are both reaching a stage of maturity
where it may be possible for large pharma to make a commercial decision that "EFTI"
could well be worth investing in.....Immutep's exceptional patent strategy that allows
individual cancer indication treatments to be available for singular targets means
big pharma could make an offer for "EFTI" just for combos for Head and neck cancer
and the company's major checkpoint inhibitor, keytruda for example...
The patent structure theoretically would allow GSK to make an offer for say
breast cancer, BMS for lung cancer etc.....
I:E "EFTI" could possibly be outlicensed to different pharma for different treatments...
Entirely relies on positive data, data is all that matters...and it's commercial worth..
Telling coupla months for immutep....starting this week...